- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:22 | Lexaria geht Partnerschaft mit PegBio zur Verabreichung von GLP-1-Wirkstoffen ein | 5 | Investing.com Deutsch | ||
| 15:18 | Lexaria enters partnership with PegBio for GLP-1 drug delivery | 3 | Investing.com | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| 15:02 | Lexaria Bioscience Corp.: Lexaria Enters a Material Transfer Agreement With PegBio | 199 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into... ► Artikel lesen | |
| 10:58 | PEGBIO CO-B (02565): DATE OF BOARD MEETING | - | HKEx | ||
| 22.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT ISSUANCE OF THE FIRST BATCH OF COMMERCIAL PRESCRIPTIONS OF PAIDAKANG NATIONWIDE AND SATISFACTION OF THE CONDITIONS ... | - | HKEx | ||
| 10.07. | China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics | 2 | Yicai Global | ||
| 10.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NASDAQ-LISTED RANI THERAPEUTICS TO ADVANCE ORAL DELIVERY OF MULTIPLE INNOVATIVE METABOLIC ... | 3 | HKEx | ||
| 09.07. | Rani Therapeutics partners with PegBio on obesity drugs | 1 | Investing.com | ||
| 09.07. | Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates | 149 | GlobeNewswire (Europe) | ~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity... ► Artikel lesen | |
| 29.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT ... | - | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): COMPLETION OF THE H SHARE FULL CIRCULATION | 1 | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON WEDNESDAY, JUNE 24, 2026; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR ... | 2 | HKEx | ||
| 05.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO RECEIVES FIRST ROYALTY PAYMENT OF HK$61 MILLION FROM TENRY PHARMACEUTICAL FOR VISEPEGENATIDE COMMERCIALIZATION ... | 1 | HKEx | ||
| 01.06. | PEGBIO CO-B (02565): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 24, 2026 | - | HKEx | ||
| 01.06. | PEGBIO CO-B (02565): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 01.06. | PEGBIO CO-B (02565): 2025 AGM CIRCULAR | 1 | HKEx | ||
| 01.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT CR059 ACCEPTED BY EASD 2026 AND SELECTED FOR THE ORAL DISCUSSION PRESENTATION SESSION | - | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,780 | +2,00 % | Qiagen übertrifft Erwartungen und bestätigt Prognose | DJ Qiagen übertrifft Erwartungen und bestätigt Prognose
DOW JONES--Qiagen hat im zweiten Quartal bei Umsatz und bereinigtem Gewinn besser abgeschnitten als erwartet und die Prognose bestätigt.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,55 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| EVOTEC | 3,566 | -7,38 % | EQS-News: Evotec SE: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
06.08.2026... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 383,55 | -0,72 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| BEAM THERAPEUTICS | 26,670 | -0,15 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| CULLINAN THERAPEUTICS | 19,830 | +1,17 % | Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,900 | -1,32 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| TANGO THERAPEUTICS | 25,830 | +0,98 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,170 | -0,42 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,480 | -1,28 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| VERA THERAPEUTICS | 29,660 | -1,10 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| DYNE THERAPEUTICS | 26,400 | +0,88 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| TREVI THERAPEUTICS | 17,940 | +1,18 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 6,295 | +0,72 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| BIONTECH | 80,40 | -0,74 % | BioNTech Aktie vor dem Comeback?: Die Krebs-Pipeline könnte die nächste Rally zünden! | © Foto: Rigby40 auf Pixabay (Symbolbild)Bei BioNTech krempelt man gerade wieder ordentlich die Ärmel hoch und lässt auch keinen Stein auf dem anderen. Das Impfstoffgeschäft schwächelt zwar spürbar,... ► Artikel lesen |
PEGBIO CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEGBIO CO LTD finden Sie auf Wallstreet Online.